hrcak mascot   Srce   HID

Izvorni znanstveni članak

The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study

Vlasta Vuković
Arijana Lovrenčić-Huzjan
Marijana Bosnar-Puretić
Vida Demarin

Puni tekst: engleski, pdf (152 KB) str. 145-150 preuzimanja: 1.866* citiraj
APA 6th Edition
Vuković, V., Lovrenčić-Huzjan, A., Bosnar-Puretić, M. i Demarin, V. (2009). The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study. Acta clinica Croatica, 48 (2), 145-150. Preuzeto s https://hrcak.srce.hr/40947
MLA 8th Edition
Vuković, Vlasta, et al. "The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study." Acta clinica Croatica, vol. 48, br. 2, 2009, str. 145-150. https://hrcak.srce.hr/40947. Citirano 16.06.2021.
Chicago 17th Edition
Vuković, Vlasta, Arijana Lovrenčić-Huzjan, Marijana Bosnar-Puretić i Vida Demarin. "The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study." Acta clinica Croatica 48, br. 2 (2009): 145-150. https://hrcak.srce.hr/40947
Harvard
Vuković, V., et al. (2009). 'The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study', Acta clinica Croatica, 48(2), str. 145-150. Preuzeto s: https://hrcak.srce.hr/40947 (Datum pristupa: 16.06.2021.)
Vancouver
Vuković V, Lovrenčić-Huzjan A, Bosnar-Puretić M, Demarin V. The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study. Acta clinica Croatica [Internet]. 2009 [pristupljeno 16.06.2021.];48(2):145-150. Dostupno na: https://hrcak.srce.hr/40947
IEEE
V. Vuković, A. Lovrenčić-Huzjan, M. Bosnar-Puretić i V. Demarin, "The Efficacy of Gabapentin in Migraine Prophylaxis: An Observational Open Label Study", Acta clinica Croatica, vol.48, br. 2, str. 145-150, 2009. [Online]. Dostupno na: https://hrcak.srce.hr/40947. [Citirano: 16.06.2021.]

Sažetak
Migraine is often a chronic and disabling disorder. The objective of our study was to assess the efficacy and safety of gabapentin in the prophylaxis of migraine in patients' refractory to other prophylactic treatments. The study included 67 migraine patients, 55 women and 12 men; 52 patients completed this prospective, open-label study. Patients were given 900-1800 mg of gabapentin in 3 doses; the mean duration of treatment was 7.2 months. Reduction in the number of days with headache, pain intensity and number of acute medications was assessed through patient diary. The mean number of migraine days/4 weeks was reduced from 15.8 to 8.6, yielding a reduction of 7.2 migraine days/4 weeks (P=0.001). Pain intensity was reduced by 25% in 14 (26.9%), by 50% in 29 (55.7%) and by 75% in three (5.7%) patients, whereas no improvement was reported by six (11.5%) patients at the end of follow up. A significant reduction was recorded in acute medication use (P=0.001). Adverse events were reported by 32/67 (47.8%) patients, in 15 (22.4%) of them causing discontinuation of the drug. The most frequently reported adverse events were drowsiness, dizziness and slowness. Prophylactic treatment with gabapentin was found to be associated with a significant reduction in the number of days with headache, use of acute medications and pain intensity.

Ključne riječi
Migraine - therapy; Migraine - prevention and control; Headache - therapy; Headache - prevention and control

Hrčak ID: 40947

URI
https://hrcak.srce.hr/40947

[hrvatski]

Posjeta: 2.441 *